Literature DB >> 23133084

Perspectives of tumour markers in gastrointestinal malignancies - an overview.

Vijayashree Murthy1, K S Gopinath.   

Abstract

There is an increasing incidence of GI cancers as per the Cancer Registry Data. In such a situation, it is essential to evaluate the patient by standard investigational tools like clinical examination and endoscopy which help in establishing the diagnosis. Determination of tumour markers is useful not only in diagnosis and prognosis of cancer but also monitoring of cancer treatment. Tumour markers in GI oncology include oncofoetal proteins, hormones, enzymes and cancer antigens. Recent advances include application of tumour marker level determination combined with newer radiological and functional imaging such as FDG PET - CT.

Entities:  

Keywords:  CEA; GI malignancies; Tumour markers

Year:  2008        PMID: 23133084      PMCID: PMC3452363          DOI: 10.1007/s12262-008-0083-z

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  23 in total

1.  Microsatellite instability.

Authors:  Albert de la Chapelle
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

2.  Production of embryonal alpha-globulin by transplantable mouse hepatomas.

Authors:  G I ABELEV; S D PEROVA; N I KHRAMKOVA; Z A POSTNIKOVA; I S IRLIN
Journal:  Transplantation       Date:  1963-04       Impact factor: 4.939

3.  CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.

Authors:  D Pectasides; A Mylonakis; M Kostopoulou; M Papadopoulou; D Triantafillis; J Varthalitis; M Dimitriades; A Athanassiou
Journal:  Am J Clin Oncol       Date:  1997-08       Impact factor: 2.339

4.  Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer.

Authors:  Y Ikeda; H Oomori; N Koyanagi; M Mori; T Kamakura; S Minagawa; H Tateishi; K Sugimachi
Journal:  Oncology       Date:  1995 Nov-Dec       Impact factor: 2.935

5.  Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Authors:  R A Abrams; L B Grochow; A Chakravarthy; T A Sohn; M L Zahurak; T L Haulk; S Ord; R H Hruban; K D Lillemoe; H A Pitt; J L Cameron; C J Yeo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

Review 6.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

7.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authors:  Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

8.  Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  K R McIntire; C L Vogel; A Primack; T A Waldmann; S K Kyalwazi
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

9.  CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma.

Authors:  E W Martin; J P Minton; L C Carey
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

10.  Specific carcinoembryonic antigens of the human digestive system.

Authors:  P Gold; S O Freedman
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.